SCNX News & Events

Scienture announced that it has formalized multiple commercial Group Purchasing Organization, GPO, agreements for Rezenopy Nasal Spray 10 mg, providing access to more than 5000 healthcare institutions, including hospitals, clinics and nursing homes, representing potential penetration into roughly 60% of the U.S. institutional market while also establishing a broad footprint across first responders, EMS providers and rehabilitation centers. "These GPO agreements represent a significant step forward in the commercial expansion of Rezenopy," commented Narasimhan Mani, President and co-CEO of Scienture. "They meaningfully expand our institutional reach, providing access to more than 5000 healthcare facilities representing potential penetration into approximately 60% of the U.S. institutional market. With the U.S. naloxone market representing approximately $141 million in annual sales and 9.4 million prescription units, we believe Rezenopy, the highest-dose FDA-approved naloxone nasal spray, is well positioned to drive broader adoption and capture market share as we continue executing our commercialization strategy."

Scienture provided a commercial update on Arbli oral suspension, the first and only FDA-approved ready-to-use oral liquid formulation of losartan, alongside key market access achievements, financial strengthening initiatives, and near-term outlook-including reaffirming its plan to commercially launch Rezenopy, a life-saving opioid overdose emergency treatment, in the second quarter of 2026. Over the past four months, Scienture has executed a series of commercial, payer and patient-focused initiatives designed to materially expand access to Arbli across retail, institutional, and managed care channels within the approximately $241 million in total annual sales and 72 million prescriptions U.S. losartan market.

Scienture announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering REZENOPY Nasal Spray 10 mg, effective January 6, 2026, with an expiry date of February 5, 2041. The patent was issued to Summit Biosciences, a subsidiary of Kindeva Drug Delivery L.P. As previously disclosed, Scienture, a wholly owned subsidiary of Scienture Holdings, entered into a definitive agreement with Summit in March 2025 for the exclusive U.S. commercialization rights to REZENOPY. Under the terms of the collaboration, Summit will manufacture and commercially supply REZENOPY. Pending certain commercial obligations, Scienture will own the new drug application, NDA, for REZENOPY in its name and be responsible for the sales, marketing and distribution of the product in the U.S. through Scienture's commercial operations infrastructure.